Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms ...

Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...

Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

REUP avoids the ethical issues and costs of other procurement and recovery methods. So far, outcomes are excellent.

Background Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) carries high mortality. Early ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

Women with moderate-to-severe aortic regurgitation managed without surgery show worse survival than men. Measures of left ...

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million ...